Current treatment status-Undergoing active treatment-Progressive despite several lines of treatment - Page 13 of 24 Posts on Medivizor
Navigation Menu

Current treatment status-Undergoing active treatment-Progressive despite several lines of treatment Posts on Medivizor

The use of brentuximab vedotin before transplant for patients with Hodgkin’s lymphoma

The use of brentuximab vedotin before transplant for patients with Hodgkin’s lymphoma

Posted by on Mar 29, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study aimed to compare outcomes for patients with Hodgkin’s lymphoma who received brentuximab vedotin (Adcetris) compared to chemotherapy before a stem cell transplant. This study concluded that patients who received brentuximab vedotin had a better survival. Some background Allogeneic hematopoietic stem cell...

Read More

Comparing conditioning regimens before stem cell transplantation for patients with Hodgkin lymphoma

Posted by on Mar 28, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of two chemotherapy regimens before autologous stem cell transplantation (ASCT) for patients with Hodgkin lymphoma (HL). This study concluded that BEAM conditioning before ASCT significantly improved the outcomes of these patients. Some background About 20 – 30% of patients...

Read More

The impact of graft-versus-lymphoma effect on outcomes after reduced intensity conditioned stem cell transplant

The impact of graft-versus-lymphoma effect on outcomes after reduced intensity conditioned stem cell transplant

Posted by on Mar 26, 2019 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the impact of the graft-versus-lymphoma effect on the outcomes for patients with leukemia/lymphoma who are treated with reduced-intensity conditioning (RIC) with alemtuzumab (Lemtrada) allogeneic hematopoietic stem cell transplant (allo-HSCT).  This study concluded that the graft-versus-lymphoma effect...

Read More

Looking for patients with lung cancer to test a new drug

Looking for patients with lung cancer to test a new drug

Posted by on Mar 26, 2019 in Lung cancer | 0 comments

In a nutshell This phase 2 trial will investigate the safety and effectiveness of tisotumab vedotin (TTV) for the treatment of solid tumors. The main outcome will be the response rate to treatment. This trial will take place in the United States, France, and Italy. The details Non-small cell lung cancer (NSCLC) is caused by excessive cell growth in...

Read More

Allogenic hematopoietic stem cell transplant for patients with unresponsive acute myeloid leukemia

Allogenic hematopoietic stem cell transplant for patients with unresponsive acute myeloid leukemia

Posted by on Mar 20, 2019 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the effectiveness of allogeneic hemopoietic stem cell transplant (alloHSCT) in patients with unresponsive acute myeloid leukemia. This study concluded that alloHSCT is the best treatment option for these patients. Some background Patients with unresponsive acute myeloid leukemia (AML) are those...

Read More

Searching for patients to try a new therapy for non-responsive leukemia/lymphoma after stem-cell transplant.

Posted by on Mar 15, 2019 in Leukemia | 0 comments

In a nutshell This study will investigate the effects of ibrutinib (Imbruvica) in patients with non-responsive leukemia/lymphoma after a stem-cell transplant. The main outcome that will be measured is the time after treatment before patients experience cancer worsening. This trial is recruiting in the United States. The details Some patients with...

Read More

Searching for patients to try a new therapy for non-responsive lymphoma after stem-cell transplant.

Posted by on Mar 15, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study will investigate the effects of ibrutinib (Imbruvica) in patients with non-responsive lymphoma after a stem-cell transplant. The main outcome that will be measured is the time after treatment before patients experience cancer worsening. This trial is recruiting in the United States. The details Some patients with lymphoma...

Read More

Searching for patients with relapsed or unresponsive classical HL to try this new treatment option

Posted by on Mar 15, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This Phase 3 trial is evaluating the effectiveness of brentuximab vedotin (Adcetris) with or without nivolumab (Opdivo) for patients with relapsed or unresponsive classical Hodgkin’s lymphoma (cHL). The main outcome to be measured will be survival outcomes at 4 years after treatment. The details Treatment remains...

Read More

Is entospletinib an effective treatment for relapsed or unresponsive chronic lymphocytic leukemia?

Is entospletinib an effective treatment for relapsed or unresponsive chronic lymphocytic leukemia?

Posted by on Mar 12, 2019 in Leukemia | 0 comments

In a nutshell This study examined if entospletinib can be used as a treatment for relapsed or unresponsive chronic lymphocytic leukemia (CLL). This study concluded entospletinib has disease reducing activity in patients with CLL, where previous treatment has failed. Some background Chronic lymphocytic leukemia (CLL) is a cancer of the bone marrow. It...

Read More

Evaluating carfilzomib plus dexamethasone for relapsed or refractory multiple myeloma

Evaluating carfilzomib plus dexamethasone for relapsed or refractory multiple myeloma

Posted by on Mar 10, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the impact of carfilzomib (Kyprolis) and dexamethasone (Decadron) on quality of life for patients with relapsed or refractory (does not respond to treatment) multiple myeloma (MM). This study concluded that patients treated with this combination had a higher quality of life. Some background MM is a...

Read More

Combining ibrutinib and umbralisib to treat relapsed/unresponsive chronic lymphocytic leukemia

Combining ibrutinib and umbralisib to treat relapsed/unresponsive chronic lymphocytic leukemia

Posted by on Feb 28, 2019 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of ibrutinib (Imbruvica) combined with umbralisib for patients with released/unresponsive chronic lymphocytic leukemia (CLL). This study concluded that the combination of umbralisib and ibrutinib is well tolerated and effective in relapsed/unresponsive CLL.  Some background...

Read More